Is Aktis Oncology, Inc. (AKTS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 28.6% / 30% | 0.0% / 30% | 544.92% / 5% | ✗ NOT HALAL |
| DJIM | 1.2% / 33% | 28.6% / 33% | 0.0% / 33% | 544.92% / 5% | ✗ NOT HALAL |
| MSCI | 3.7% / 33% | 91.1% / 33% | 0.0% / 33% | 544.92% / 5% | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 28.6% / 33% | 0.0% / 33% | 544.92% / 5% | ✗ NOT HALAL |
| FTSE | 3.7% / 33% | 91.1% / 33% | 0.0% / 50% | 544.92% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -1675.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -26.5% | |
| Return on Assets (ROA) | -14.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $15M |
| Free Cash Flow | $12M |
| Total Debt | $12M |
| Debt-to-Equity | 4.9 |
| Current Ratio | 9.3 |
| Total Assets | $326M |
Price & Trading
| Last Close | $17.62 |
| 50-Day MA | $19.33 |
| 200-Day MA | $19.50 |
| Avg Volume | 406K |
|
52-Week Range
$14.89
| |
About Aktis Oncology, Inc. (AKTS)
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Aktis Oncology, Inc. (AKTS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aktis Oncology, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Aktis Oncology, Inc.'s debt ratio?
Aktis Oncology, Inc.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.7%.
What are Aktis Oncology, Inc.'s key financial metrics?
Aktis Oncology, Inc. has a market capitalization of $838M, and revenue of $1M. Return on equity stands at -26.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.